Bausch + Lomb (BLCO) Scheduled to Post Quarterly Earnings on Wednesday

Bausch + Lomb (NYSE:BLCO) is set to announce its earnings results before the market opens on Wednesday, May 1st. Analysts expect the company to announce earnings of $0.09 per share for the quarter. Bausch + Lomb has set its FY 2024 guidance at EPS.Parties interested in participating in the company’s conference call can do so using this link.

Bausch + Lomb (NYSE:BLCO) last issued its quarterly earnings data on Wednesday, February 21st. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.17 by $0.07. The company had revenue of $1.17 billion during the quarter, compared to analysts’ expectations of $1.11 billion. Bausch + Lomb had a positive return on equity of 3.70% and a negative net margin of 6.27%. The business’s revenue was up 17.8% on a year-over-year basis. During the same period last year, the business earned $0.23 earnings per share. On average, analysts expect Bausch + Lomb to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Bausch + Lomb Price Performance

Shares of Bausch + Lomb stock opened at $15.14 on Tuesday. Bausch + Lomb has a 1-year low of $13.62 and a 1-year high of $21.95. The firm’s 50-day moving average price is $15.97 and its two-hundred day moving average price is $15.67. The company has a current ratio of 1.74, a quick ratio of 1.09 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $5.32 billion, a price-to-earnings ratio of -20.45, a P/E/G ratio of 1.43 and a beta of 0.36.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on BLCO shares. Royal Bank of Canada dropped their price target on Bausch + Lomb from $20.00 to $18.00 and set an “outperform” rating for the company in a report on Monday, April 22nd. Evercore ISI raised their price objective on shares of Bausch + Lomb from $16.50 to $17.00 and gave the company an “in-line” rating in a research report on Thursday, April 4th. Wells Fargo & Company raised their price target on shares of Bausch + Lomb from $21.00 to $23.00 and gave the company an “overweight” rating in a report on Thursday, February 22nd. Barclays upped their price objective on Bausch + Lomb from $17.00 to $18.00 and gave the stock an “equal weight” rating in a report on Monday, February 26th. Finally, Evercore lowered their target price on Bausch + Lomb from $17.00 to $16.50 and set an “in-line” rating for the company in a research note on Thursday, February 22nd. Five equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, Bausch + Lomb has a consensus rating of “Moderate Buy” and a consensus target price of $19.50.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.